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CD4 is a 55-kD glycoprotein found predominantly on the surface ofa subset of
T lymphocytes. This monomeric surface protein has an extracellular region of 372
amino acids, a single transmembrane segmentof 21 residues, andashort cytoplasmic
region of40 residues . The extracellular region consists offourtandem domains that
have sequence and predicted structural homology with Ig L chainV regions (1, 2) .
On lymphocytes, CD4 defines T cells that recognize antigen presented by MHC
class II-bearing cells . In this interaction, CD4 appears to promote efficient T cell
activation through binding to a monomorphic determinant on the class II proteins
of thepresenting cell . This association with class II proteins may increase the avidity
of theinteraction betweentheTcellandAPC (3-5) . However, the recently observed
association of the T cell-specific tyrosine kinase p56ick with CD4 (6, 7) also sug-
gests a direct role for CD4 in signal transduction in response to antigen presenta-
tion. This potentially complex role ofCD4may explain the reported inhibition (8-16)
or enhancement (17-19) of the T cell response in vitro by different CD4 mAbs .
In man, CD4 is also the target for virus attachment by HIV (20-22), a process
mediated by the viral envelope glycoprotein gp120 (23) . Through extensive genetic
analysis, the binding site for gp120 on CD4 was localized within the first Ig-likedo-
main, V1, to a predicted loop structure of ti 12 amino acids (24-28) . Based on the
sequence alignment of V, with human tc chain V domains (V,,), we and others
(24-28) have proposed that the gp120-binding site encompasses a region within Vt
that corresponds to the complimentarity-determining region 2 (CDR2) 1 of Ig L
chains. In this report we provide evidence for this model of theV1 domain through
epitope mapping of a panel of 26 CD4 mAbs .
Address correspondence toA. Truneh, Department of Immunology, SmithKline & French Laborato-
ries, 709 Swedeland Road, King of Prussia, PA 19406 .
1 Abbreviations used in this paper . CDR, complimentarity-determining region; KLH, keyhole limpet
hemacyanin .
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EPITOPE MAPPING OF CD4
Previous studies have grouped a panel of CD4 mAbs on the basis oftheir crossin-
terference in binding to CD4+ cells and their ability to inhibit HIVinduced syn-
cytium formation of CD4+ cells (29, 30). We have extended the crossinterference
analysis to include additional antibodies and have regionally localized the binding
sitesof the mAbs using truncated soluble CD4 proteins. The epitopes for theseanti-
bodies were then defined with a panel ofsingle and multiple aminoacid substitution
mutants in the V 1 region. Finally, the fine specificity ofa subset ofthese antibodies
was compared in crossblocking studies with polyclonal and monoclonal anti-idiotype
antibodies.
Several antigenically distinct sites were identified within the V, domain, some of
which were common to many antibodies. Most of the epitopes mapped to sites of
predicted exposed loops, with the predominant sites lying within sequences corre-
sponding to CDRI, -2, and -3 in Ig L chain V regions. Epitopes for two groups
of mAbs consisted of nonlinear sequences spanning residues in CDRI and -2 or in
CDR1 and -3, regions predicted to be close in space in an Ig fold.
Our results agree with and extend other analyses of CD4 mAb epitopes (24, 25,
27, 29, 31) and support a V-like structure for the V1 domain of CD4. This epi-
tope analysis also has significant implications for an HIV vaccine strategy predi-
cated on the development of anti-idiotype antibodies against CD4 mAbs.
Materials and Methods
Soluble CD4andDerivedMutants.
￿
The soluble CD4 protein, consisting ofonly the extracel-
lular domains of CD4, truncated derivatives, and site-directed mutants were expressed as
exported proteins in CHO cells or in Escherichia coli and isolated as previously described (28,
32, 33).
Expression of CD4 Lacking the V4 Domain.
￿
Using synthetic linkers, the V4 region of CD4
was deleted from the plasmid pT4 (1) to yield pT4DV4, in which residues -23-253 are fused
to residues 299-437 . This DV4 coding sequence was introduced into HeLa cells using the
retroviral vector pMV7, as previously described for CD4 (22). Cell clones were screened for
expression of the AV4 protein by immunoblot analysis with a polyclonal antibody prepared
against a recombinant CD4 protein expressed in E. coli. HeLa cellstransfected with the OV4
gene expressed a 40-kD CD4 protein as compared with a 56-kD protein in cells transfected
with the full-length CD4 gene (not shown).
mAbs.
￿
Many of the CD4 mAbs were obtained through the Third International Work-
shop on Leukocyte Differentiation Antigens (1986). Others were obtained from the following
sources: Leu 3a (N. Warner, Becton Dickinson & Co., Mountain View,CA); OKT4, OKT4A,
OKT4B, OKT4C, OKT4D, OKT4E, and OKT4F (P Rao, Ortho Diagnostic Systems Inc.,
Westwood, MA); F101-69,111-364, and F14 (P Poncelet, Sanofi Corp., Montpellier,France);
RFT4 (G. Janossy, Royal Free Hospital, London, UK); NUTH/1 (M. M. Yokoyama, Ku-
rame University, Kuyume, Japan); and MT310 and MT151 (P Reiber and G. Reithmuller,
Munich University).
Mapping ofmAb Epitopes with CD4 Mutants.
￿
Mutant soluble CD4 proteins were used to
inhibit the binding of CD4 mAbs to SupT1 cells. Antibodies at concentrations of between
10 and 50 ng/ml were incubated for 30 min with a 10-fold excess of inhibitory protein, in
a total volume of 50 pl. 50 pl of cells at 2 x 106/ml was then added. After 30 min, the cells
were washed and labeled with FITC-conjugated goat anti-mouse IgG. 30 min later, the cells
were washed and analyzed by flow cytometry on an EPICS 753 (Coulter Electronics Inc.,
Hialeah, FL). All incubations were done at 4°C. Background fluorescence was determined
on cells stained with FITC conjugate only. The results are expressed as the mean fluores-
cence intensity ofSupT1 cell staining. For negative controls, conditioned medium from CHO
cells or E. colinot expressing CD4 were processed as for cells expressing CD4 proteins. These
preparations gave values equivalent to the staining without CD4 proteins. Percent blockingSATTENTAU ET AL.
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with each CD4 mutant protein was computed by: 100 x [(MF, - MFm)/(MF~ - MF,)],
where MF is the mean channel fluorescence without CD4 protein (c), with mutant protein
(m), and with V,V2 soluble CD4 protein standards (s).
Preparation ofAnti-idiotypes to CD4 mAbs.
￿
CD4 mAbs at a concentration of 1 mg/ml were
coupled to an equivalent amount ofKeyhole Limpet hemocyanin (KLH) with 0.1% glutaralde-
hyde in PBS-A for 1 h at room temperature, then dialyzed against 1,000 vol ofPBS-A. BALB/c
mice were immunized with 100 mg ofthe mAb/KLH conjugate in CFA. 1 mo later, the same
amount of antigen was administered in IFA. Mice were then bled -10 d afterthe last immu-
nization, and sera tested for anti-idiotypic activity. Further immunizations consisted of the
antibody alone without carrier or adjuvant. mAbs were prepared from mice immunized as
above by standard procedures (34).
Assay ofAnti-idiotypeAntibodies.
￿
CD4 mAbs were labeled with '251 as previously described
(29). A dilution of labeled mAb yielding "2,000 cpm of specific CD4 binding activity was
mixed with dilutions of anti-idiotype antisera or mAb, incubated for 30 min at 4°C, then
added to "106 CEM cells. Controls were normal mouse sera or control supernatants. Inhi-
bition of idiotype binding to cellular CD4 by anti-idiotype antibody was calculated by the
formula 100 - 100 x [(T - C/M - C)], where C, counts bound in the presence of saturating
amounts ofblocking anti-idiotype reagent; M, counts bound in the presence of an irrelevant
antibody or normal mouse serum; T, counts bound in the presence of anti-idiotypes raised
against different CD4 mAbs.
Crossblocking between CD4 mAbs.
￿
These were carried out as previously described (29).
Results
Crossblocking Analysis,
￿
Previous studies have defined groups of CD4 mAbs on the
basis of their ability to block the binding of selected CD4 mAbs or HIVgp120 to
CD4+ cells and to inhibit virus-induced syncytium (29, 30, 35). Interference be-
tween antibodies(or gpl20) suggests that they recognize a common surface on CD4,
although in this type ofanalysis a shared binding site cannot be readily distinguished
from inhibition by indirect conformational or steric effects. Conversely, the simul-
taneous binding of two antibodies (or gpl20) indicates that their epitopes are spa-
tially distinct, although apparent simultaneous binding may result from significant
differences in affinity. We have extended the previous studies (29, 30) by examining
the inhibition of additional antibodies. Each of a series of mAbs was labeled with
1251 and then added to CD4+ CEM cells that had been preincubated with a
saturatinglevel ofa second, unlabeled CD4 mAb. Each labeled antibody was blocked
by an excess ofthe same antibody and by some, but not all, of the other mAbs (Table
I). For example, Leu 3a was strongly inhibited by EDU-2, MT310, 111-364, 17101-69,
NUTH/1, and Leu 3a itself, moderately inhibited by OKT4A, and unaffected by
all of the othermAbs. Several ofthe antibodies gave inconsistent crossblocking results.
For example, MT151 blocked OKT4C and OKT4D (Table I) but neither antibody
blocked MT151 (29). These results, together with previous studies, suggest the fol-
lowing grouping of the antibodies: (a) EDU-2, MT310, 111-364, 17101-69, 17101-5,
Leu 3a, T4/18T3A9, T4/19Thy-5D7, 91d6, 94b1, NUTH/1, and to a lesser extent,
CLBT4/1 and OKT4A; (b) OKT4Dand RFT4; and (c) VIT4, MT321, and MT151.
Set a is the best defined due to a more extensive crossblocking analysis of this collec-
tion of antibodies.
Domain Mapping with Truncated, Soluble CD4 Proteins.
￿
We have described the ex-
pression and characterization of a soluble form of the CD4 protein, consisting of
the entire extracellular domain of this receptor (32), and truncated derivatives con-
sisting of the first two NH2-terminal domains (V IVJ4) or the first domain alone1322
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TABLE I
Crosscompetition between 1251-labeled and Unlabeled CD4 mAbs
Binding of 125I-labeled CD4 mAbs to CD4* SupT1 cells pretreated with unlabeled CD4 mAbs was deter-
mined. Scores represent percentage inhibition ofbinding oflabeled mAb by saturating concentrations of un-
labeled mAb. + + , >80% inhibition oflabeled mAb binding; + , 20-79% inhibition; and - , <20% inhibition.
(V1) (28, 32). We used these soluble CD4 proteins to localize the binding of 26
mAbs to specific domainsof CD4by measuringtheirability to block antibody binding
to the CD4+ cell line, SupT1. The results define three groups of antibodies (Fig. 1):
group 1 (V1 mAbs), those blocked by all three proteins; group 2 (VIV2 mAbs), those
blocked by V1V2J4 and soluble CD4 but not by V1 ; and group 3 (V3V4 mAbs),
those blocked only by soluble CD4. As in previous studies with amore limited panel
of antibodies (24), all of the mAbs were blocked by soluble CD4 and all but one,
OKT4, was blocked by the V1V2J4 protein. This localization of the OKT4 epitope
agrees with other similar studies (33, 36) and with the absence of this epitope on
aV4 deletion mutant of CD4 expressed on the cell surface (Fig. 2). 13 of the mAbs
were inhibited by the V1 protein, indicating that the determinants of high affinity
binding for these antibodies reside within the V1 domain. Two antibodies, VIT4
and OKT4F, were partially inhibited by V1, suggesting that a portion of their epi-
tope is within this domain. The epitopes for the mAbs blocked by V1V2J4 but not
by V1 may lie only in V2 or may span V1 and V2 . Alternatively, some regions of
the V1 protein may not be properly folded, therebydisrupting some epitopes within
this domain.
The set a and b antibodies defined by the crossblocking studies in the previous
section all map to the V1 domain. These antibodies also efficiently inhibit infec-
tion by HIV and SIV an observation consistent with the recent localization of the
gp120-binding site to this domain of CD4 (24-28).
Mapping of the Epitopes within the Vi Domain.
￿
To define the antibody epitopes
residing wholly or partially within the V1 domain, we used a collection of single
and multiple substitution mutations introduced into this region and expressed in
the context of V1V2 or full-length soluble CD4 proteins (28). To induce only local
disruption of structure, the V1 region of the murine CD4 protein, which shares
-50% sequence homology with the human V1 sequence, was used as a template
Unlabeled
mAbs EDU-2 MT310 111-364 F101-69
125I-labeled
Leu 3a
mAbs
OKT4A OKT4D OKT4C OKT4F
EDU-2 ++ ++ ++ ++ ++ ++ ++ - -
MT310 ++ ++ ++ ++ ++ ++ ++ - -
111-364 ++ ++ ++ ++ ++ ++ ++ - -
F101-69 ++ ++ ++ ++ ++ ++ ++ - -
Leu3a ++ ++ ++ ++ ++ ++ ++ - -
NU-TH/l ++ ++ ++ ++ ++ + - ++ +
OKT4A + + + + + + + - - + +
RFT4 - - - - - - + + + -
OKT4D - - - - - - + + - +
66.1 - - - - - + + - ++
OKT4C - - - - - - - + + -
OKT4E - - - - - - - + + -
MT151 - - - - - + ++ ++ -
OKT4F - - - - - + - - + +SATTENTAU ET AL .
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FIGURE 1 .
￿
Assignment ofCD4mAb reactivities to Ig-like domains ofCD4. Antibodies were
incubated with full-length soluble CD4, VIV2j4, orV1 proteins as indicated before addition of
SUPT-1 cells . The results are expressed as percent inhibition relative to the level of staining in
the absence ofCD4 protein . Inhibition ofmAb binding to aCD4* T cell line, SUPTI, by sCD4,
V1V2, and V1 . (A) mAbs blocked by all three proteins ; (B) by sCD4 and V1V2 ; or (C) or by
sCD4 only.
formutagenesis . Thus, at positions wherethetwo sequencesdiffered, mouseresidues
were substituted in place of the corresponding human amino acids; for example,
ME is the substitution of glutamic acid for lysine at residue 8 ofhumanCD4. The
fact that themutantsincorporatedhumanto mouseresidue switches whilethe panel
ofCD4mAbs used for the mapping study were generated in mice may account for
our ability to differentiate between mAbs that map close to each other on Vi .
FIGURE 2 .
￿
Lack of reactivity
of OKT4 with HeLa cells ex-
pressing T4AV4 . HeLa cell
transfectants were analyzed by
flow cytometry after staining
with FITC-conjugated mAbs .
Histograms represent the rela-
tive mean fluorescence after
subtraction of background
values . Cell surface expression
offull-lengthCD4was detected
with OKT4 as well as Leu 3a
but not with the control CDS
antibody (Leu 2a) while the
T4AV4 was detected only by
Leu 3a.1324
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Theeffect ofthesemutationsonantibody bindingwas assessed as describedabove
for thedomain analysis. Each mAb was incubated withanexcess ofthemutant pro-
tein before addition to SupTl cells and binding was measured by flow cytometry.
The results ofthese assays are summarized in Table II. Comparable results for Leu
3a, OKT4A, and 13118.2 were obtained in an ELISA (Table II, legend). None of
the mutations affected all ofthe antibodies, indicatingthateach mutation does cause
only local perturbation of structure. Among the group 1 (Vi) antibodies defined
above, all were strongly affected by mutations in the region 42-43; all except NU-
TH/1 were inhibited by mutations at 24-27. Some ofthis group were also strongly
affected by the phenylalanine substitution at position 55 and partially affected by
mutations at 34, 40, and45. Although each mAb in this group shows a distinct pat-
tern ofreactivity to mutant CD4 proteins, the common disruption oftheir epitopes
by mutationsat 42-43, and often at 24-27, is consistent with the crossblockingresults
described in Table I. We have designated this set ofantibodies as group lA (Table
II), to distinguish them from the other group 1 mAbs. The other four Vi antibodies
were not affected by the substitutions at 42-43 and each showed a different pattern
ofblockingby the panel ofmutants. OKT4A is weakly disruptedby the double mu-
tation at 64-66, a result verified in a competition ELISA (Table 11, legend). Re-
cently, we found that mutation ofthe serine residue at position 60 specifically dis-
rupts OKT4A binding (Ping Tsui, unpublished observations) in agreement with
a previous report (24). 13B8.2 is affected only by the mutation at residues 88-89.
OKT4D and RFT4 were commonly disrupted by alterations at residues 34 and 55,
although to different extents, a result in agreement with the blocking of OKT4D
binding by RFT4 (Table I). However, unlike OKT4D, RFT4 was also affected by
the mutation at position 27.
All ofthe group 2 mAbs were affected by one or more mutations within the V 1
region (Table II), suggesting that their epitopes reside at least partially within the
V1 domain. The results suggest two general groupings ofthese antibodies. Group
2A(OKT4C, OKT4E, F14, MT321, andVIT4) were primarilyaffected by the sub-
stitutions at both 24-25 and 88-89; whereas group 211 (BLVIOT4, OKT4B, and
MT151) were most affected by the mutation at 94-96. OKT4E and F14 were also
moderately disruptedby the 42-43 alteration and BLVIOT4was severelyperturbed
by themutation at amino acid8. OKT4F and11264/123did not match either group.
OKT4Fwasuniquelydisrupted bythe extensive mutation spanning residues 102-105.
Among themutants examined with 11264/123, those atthe NH2 terminus and 88-89
had the greatest effect.
In summary, most ofthe mAbs fall into one of the three groups (1A, 2A, or 211)
based on the pattern of disruption by the substitution mutants. The predominant
epitopes appear to reside at or nearresidues 24-27, 42-43, and88-96. The epitopes
forthe majorityofthese mAbsappear to benonlinear. OfthesemAbs, thosereactive
with the Vi domain alone recognize epitopes affected by mutations at residues
24-27 and at 42-43, whereas those reactive with V,VJ4, but not V1, recognize epi-
topes primarily affected by mutations at 24-25 and at 88-89.
Previously, we have used this same collection of mutants to define the binding
site for HIV gp120 (28) and the results of that analysis are summarized in Table
II. Similar to some ofthe group 1A mAbs, gp120 binds to the V, protein and its
recognition is selectively disrupted by the mutations at 42-43 and 55. Interestingly,SATTENTAU ET AL.
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however, none of these antibodies are affected by the mutants in a manner identical
to gp120. Thus, the gp120 binding site differs from that of the group 1A mAbs.
Anti-idiotype Analysis. Crossblocking studies with anti-idiotypic antibodies pro-
vide a highly specific approach for identifying shared epitopes between mAbs. An
anti-idiotype raised against the combining site of one mAb is likely to bind to other
mAbs that recognize the same epitope. We measured the ability of anti-idiotypes
developed againstselected group IA mAbs to block the binding ofother CD4 mAbs
to CD4+ CEM cells. This approach to mapping shared epitopes is more specific
than crossblocking analyses and avoids the conformational and steric effects that
may result from two antibodies binding to CD4.
Table III presents the resultsobtained with polyclonal anti-idiotype antisera raised
to some group 1A antibodies. All ofthe anti-idiotype antisera completely inhibited
their own idiotypes. In addition, each of the antisera also inhibited the binding of
most of the other group 1A mAbs examined, but did not inhibit either MT151 or
OKT4. Table IV presents the results obtained with anti-idiotype mAbs raised against
the group IA mAbs MT310, F101-69, and NUTH/1. Each antibody blocked its idio-
type, but only one, F101-69/2H10, weakly blocked any of the other group IA mAbs.
We conclude from the crossblocking by the polyclonal anti-idiotype antisera that
the group IA mAbs recognize very similarepitopes. Apparently, most ofthe mono-
clonal anti-idiotypes we examined were not directed against this common recogni-
tion site.
The VRegion ofREIas a Modelfor the Vi Domain.
￿
The Vt domain of CD4 shares
sequence and predicted structural homology with Ig Kchain V regions (1, 2). Among
human VK regions whose structure have been determined, V1 most closely aligns
with that of the BenceJones protein REI (26, 28). In the alignment shown in Fig.
3 a, 10 of the 18 invariant residues in VKdomains are analogously positioned in Vt .
Based on this alignment, we have superposed the residue numbers of V, on an u
carbon trace (37) of one V domain in REI (Fig. 3 b).
VK regions are composed of nine antiparallel a strands that are folded into two
parallel /3-pleated sheets (37, 38). Six exposed loop regions lie parallel to, and pro-
1 OKT4
"'I-labeled CD4 rnAbs were preincubated with saturating concentrations ofanti-idiotypic an-
tisera and then added to SupT1 cells. Results are expressed as the index of inhibition of la-
beled rnAb binding where: + +, >80% inhibition, +, 20-79% inhibition; and -, <20%
inhibition.
TABLE III
Blocking of mAb Binding to CD4+ Cells by Anti-idiotypic Antisera
Anti-id Anti-CD4 mAbs
antisera EDU-2 MT310 F101-69 Leu 3a NU-TH/1 MT1
EDU-2 + + + + + + + + +
MT310 - + + + + +
F101-69 + + + + + + - -
Leu 3a + + + + + -
NU-TH/l + + + + + + - + +SATTENTAU ET AL.
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TABLE IV
Blocking of mAb Binding to CD4+ Cells by Anti-idiotypic mAbs
1251-labeled CD4 mAbs were preincubated with saturating concentrations of anti-idiotypic
cnAbs and then added to SupT1 cells. Results are expressed as the index of inhibition of la-
beled mAb binding where: + +, >80% inhibition, +, 20-79% inhibition; and -, <20%
inhibition.
truding from, the planes formed by these two /3 sheets. Three of these loops form
the three CDRs (CDR1-3), which together with the corresponding regions in the
Hchain V segment comprise the antigen-binding site. The CDR regions and the
loop-encompassing residues 59-66 in Fig. 3 b project from one end of the /3 sheet
and lie relatively closeto eachother. In thealignment with REI(Fig. 3 a), the residues
in V1 corresponding to CDR1, -2, and -3 are 17-27, 43-49, and 85-97, respectively.
In the context ofthis model, most ofthe antibody epitopes defined by the muta-
genesis ofV1 occur in the exposed loops. The group 1A mAbs are primarily affected
by mutations at 24-27 and at 42-43, regions that lie within the predicted CDRI
andCDR2 loops (Fig. 3 c). Some ofthese mAbs are also affected by the substitution
ofphenylalanine foralanine at position 55. This residue lies in the /3 sheet platform
supporting CDR2 and the introduction ofthe bulky phenyl group is likely to par-
tially distort this region. The OKT4A epitope lies in the 59-66 loop, in agreement
with other reports (24, 27). RFT4 and OKT4D appear to recognize, in part, a turn
near residue 34 (Fig. 3 c). The group 2A mAbs are most affected by mutations at
24-25 and 88-89, which are in CDR1 and CDR3; group 2B mAbs are primarily
disrupted by94-96, whichis also in CDR3 (Fig. 3d). The 102-105 mutation, which
uniquely affects OKT4F, lies in theJ-like region between V1 and V2. Ifthis is the
epitope forOKT4F, the inability ofOKT4F to bind to the Vi protein suggests that
this J-like region is not properly folded in the V, protein. Other results indicate
that the OKT4F epitope lies between residues 37 and 131 (25).
The structural model for V, is also consistent with the apparent discontinuous
epitopes for the group 1A and 2A antibodies. For group 1A, residues 24-27 and
42-43 in CDRI and -2 are close in space(Fig. 3 c). Similarly, for group 2A, residues
24-27 and 88-89 in CDR1 and -3 also lie in close proximity. We thus conclude that
the V, domain ofCD4 is folded in a mannersimilarto that oftheV,, region in REI.
Anti-id
antisera
MT310
6H10
EDU-2
-
MT310
+ +
94B1
Anti-CD4
111-364
mAbs
F101-69 NU-TH/1 RFT4
F101-69
4H5 - - - - + + - +
3F9 - - - - + + - -
2H10 + + + + ++ - -
NU-TH/1
4H11 - - - - - ++
2131 - - - - - ++1328
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Discussion
Through genetic analysis, the binding site for the HIV env protein on CD4 has
been localized within the V, domain to residues 41-52 (24-28). Based on the align-
ment of the V1 domain with Ig VK consensus sequence, this site encompasses a re-
gion corresponding to CDR2 in L chain V regions. In this report, we show that
V1 bears structural similarities with V,I regions through detailed epitope mapping
of 26 CD4 mAbs. The binding sites of these mAbs were initially defined relative
to one another by crossblocking analysis andwere then localizedto specific domains
of CD4 in blocking studies with truncated, soluble CD4 proteins. These epitopes
within the V, domain were mapped in detail with a panel of 17 substitution mu-
tants, and the specificities of several mAbs that appeared to recognize very similar
epitopes were examined in crossblocking studies with anti-idiotype antibodies. The
location of the epitopes is consistent with a VK-like structure. Most of the epitopes
lie within regions of predicted exposed loops, and the apparent discontinuous epi-
topes lie closely in space.
With the exception ofOKT4, all ofthese murine mAbs bound to soluble proteins
containing only the Vi and V2 domains of CD4 (Figs. 1 and 2). This immuno-
dominance of the NH2-terminal domains is not likely to be due to sequence differ-
ences in human and mouse CD4 because the homology between these proteins is
approximately equivalent throughout the external domains. Since these mAbs were
generated against cells expressing CD4, we speculate that only limited regions of
the V3 and V4 domains are exposed on the cell surface.
All the mAbs we have examined recognize conformational epitopes as evidenced
by: (a) their inabilityto recognizedenaturedCD4proteins in immunoblots (unpub-
lished observations); (b) the disruption of binding by limited deletions outside of
their epitopes (unpublished observation); and (c) the recognition of discontinuous
epitopes by these antibodies. About half of the antibodies that bind to VIV~J4 do
not bind to V1, yet all are affected by mutations in the Vi region. The conforma-
tional nature of the epitopes recognized by the V1 antibodies argues that the Vt
protein is properly folded. Thus, the VIV2 antibodies either recognize epitopes that
span both V1 andV2, or that reside in V2 and are affected by mutations in V1. This
interpretation requires that the V, and V2 domains lie in close spatial proximity.
FIGURE 3.
￿
Modeling ofV, ofCD4on Ig V,I domains. (a) Alignment of residues 1-106ofCD4
V1 with Ig V,, domainsand REI. Shaded boxes indicate identical residues betweenthe various
sequences. Of the 18 invariant residues (>95% conservation) in VK, 10 are analogously posi-
tioned in CD4 VI (heavy shading). Based on this alignment, CD4wasmodeledon the known struc-
ture (34) ofthe BenceJones Homodimer, REI. (b) The Ig fold (35), which consists of four (for
the V,, L chain domains) pairs of antiparallel B-pleated sheetsjoined by loopsat either the NH2-
terminal or COOH-terminalendofthemolecule. Thethreehypervariable regions ofthis protein
(CDRI, -2, and -3) would be formed by the NH2-terminal loops connecting strands 1 and 2,
3 and 4, and 5 and 6. The disulphide link between the two cysteine residues defining VI is lo-
cated between strands 1 and 7, and is probably buried within the interior of the molecule. The
numbersrepresentthose forthealigned sequence oftheVI domain of CD4. The two positions
where gaps were introduced to accommodateadditional residues in V, are indicatedby broken
lines. The shaded strands representtheCDRI (UM10),CDR2 (
￿
, andCDR3 (NEW
loops. (c andd) ThepredictedmAbbindingregions forgroup 1 and group2mAbs, respectively.1330
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A similar conclusion was derived from observations that mutations in both V1 and
V2 affect the binding of certain mAbs and gp120 (24-26).
Within the V1 domain, most mAbs bind to regions corresponding to the three
CDRs in REI. The antigenicity ofthese regions is consistent with the fact that they.
are the regions of greatest divergence between mouse and human sequences and
with their presentation as exposed loops on an Ig fold. The extensive evolutionary
divergence in these regions is somewhat analogous to the hypervariable nature of
the CDRs in Igs.
Our detailed epitope analysis is relevant to a vaccine strategy for HIV based on
anti-idiotype antibodies to CD4 mAbs. Subunit vaccines based on immunization
with purified or recombinant HIV envelope proteins generally result in aweak neu-
tralizing response (39, 40). In addition, extensive antigenic drift in gp120 results
in strain-specific neutralization and rapidly leads to neutralization escape mutants
(41). However, because HIV associates with CD4, amonomorphicreceptor, the com-
bining site on gp120 is unlikely to tolerate change and is thus a target for broad-
spectrum neutralization. The high affinity binding site for gp120 is restricted to the
CDR2 loop in the Vi domain of CD4 (24-28). We have suggested that this small
loop may be accommodated by a compact binding pocket in gp120, which by its
size excludes recognition by host antibodies (28), as initially proposed by Rossman
et al. (42) for the receptor-binding site on rhinoviruses. An anti-idiotype antibody
whose epitope closely resembles the gp120-binding site on CD4 may be a better im-
munogen than gp120 itself and lead to a stronger host response to this binding site.
In previous studies, immunization ofmice with the group 1A antibody, Leu3a, elicited
an anti-idiotypic response that weakly neutralized diverse HIV isolates (43-45). This
weak response implies that Leu 3a does not precisely mimic gp120 binding to CD4,
a conclusion borne outby ourepitopemappingstudies. Moreover, none oftheother
CD4 antibodies exactly duplicated the binding pattern of gp120, and anti-idiotypes
developed against these mAbs do not bind to gp120 in ELISAs, or immunoprecipi-
tate gp120 or gp160 (unpublished results) . Epitope analysis of additional CD4 mAbs
should help identify an appropriate target for this anti-idiotype strategy.
CD4 mAbs have been used to define the physiological role of CD4 for T cell re-
sponses. Some of the mAbs that recognize epitopes within the first two NH2-
terminal domains of CD4 inhibit T lymphocyte activation while others enhance it.
In contrast, OKT4, an mAb reactive with theV3V4 region, is apparently inert (14).
Recently, mAbs againstthe murine CD4 (L3T4), possibly mimicking physiological
ligands, induced phosphorylation of the CD4-associated tyrosine kinase, p56" (46).
In this respect, mapping of the epitopes involved in the binding of CD4 with its
putative physiological ligands, MHC class II molecules, may provide insight into
the role of these molecules in T lymphocyte activation.
Summary
The CD4 molecule, a differentiation marker expressed primarily by T lympho-
cytes, plays an important role in lymphocyte activation. CD4 is also the receptor
for HIV. A number of recent studies have localized the high affinity binding site
ofthe HIV envelope glycoprotein, gp120, to the N112-terminal (VI) domain ofCD4,
a region with sequence and predicted structural homology with Ig K chain V do-
mains (VK). In this report, we show that V1 bears structural similarities with VKregions through detailed epitope mapping of 26 CD4 mAbs. The binding sites of
these mAbs were initially defined relative to one another by crossblocking analysis
and were then localized to specific domains of CD4 in blocking studies with trun-
cated, soluble CD4 proteins. The epitopes within the Vt domain were mapped in
detail with a panel of 17 substitution mutants, and the specificities of several mAbs
that appear to recognize very similar epitopes were examined in crossblocking studies
with anti-idiotype antibodies. The location of the epitopes is consistent with a VK-
like structure of Vl . Most of the epitopes lie within regions of predicted exposed
loops. A number oftheseepitopes span discontinuous residues in the linear sequence
that lies in close proximity in an Ig fold. Alignment of CD4 Vi with the Ig VK chains
places these epitopes within stretches corresponding to the complimentarity-
determining regions. This epitope analysis is relevant for a vaccine strategy for HIV
based on anti-idiotype antibodiesto CD4 mAbs and for studies with CD4 antibodies
on the role of CD4 in T lymphocyte activation.
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